• Medientyp: E-Artikel
  • Titel: How breast cancer therapies impact body image – real-world data from a prospective cohort study collecting patient-reported outcomes
  • Beteiligte: Afshar-Bakshloo, Melissa; Albers, Sarah; Richter, Chiara; Berninger, Ottilia; Blohmer, Jens-Uwe; Roehle, Robert; Speiser, Dorothee; Karsten, Maria Margarete
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: BMC Cancer
  • Sprache: Englisch
  • DOI: 10.1186/s12885-023-11172-y
  • ISSN: 1471-2407
  • Schlagwörter: Cancer Research ; Genetics ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>In breast cancer patients body image (BI) is a crucial aspect of quality of life (QoL). This study examined the postoperative impact of different surgical approaches on long-term BI analyzing real-world data to guide pre- and postoperative patient care and preserve QoL.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>EORTC QLQ-BR23 BI scores were collected electronically in 325 breast cancer patients within routine clinical care for a duration of 41.5 months (11/17/2016 – 4/30/2020) at predefined time points preoperatively and repeatedly up to two years after breast-conserving surgery (BCS) (<jats:italic>n</jats:italic> = 212), mastectomy alone (M) (<jats:italic>n</jats:italic> = 27) or mastectomy with immediate breast reconstruction (MIBR) (<jats:italic>n</jats:italic> = 86). Higher scores indicated better BI. A linear mixed regression model was used to analyze the impact of BCS, M and MIBR, as well as non-surgical therapies on BI at treatment initiation and over time.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>BI scores deteriorated by 5 points (95%-confidence interval (CI) -8.94 to -1.57, <jats:italic>p</jats:italic>≈0.005) immediately after BCS, by 7 points (95%-CI -12.13 to -1.80, <jats:italic>p</jats:italic>≈0.008) after MIBR and by 19 points (95%-CI -27.34 to -10.34, <jats:italic>p</jats:italic> &lt; 0.001) after M. The change over time after BCS (+ 0.10 points per week, 95%-CI -0.17 to 0.38), MIBR (-0.07 points per week, 95%-CI -0.35 to 0.20) and M (+ 0.14 points per week, 95%-CI -0.19 to 0.48) were not statistically significant (each <jats:italic>p</jats:italic> &gt; 0.05). At treatment initiation chemotherapy was associated with a 22-point decline (95%-CI -25.39 to -17.87, <jats:italic>p</jats:italic> &lt; 0.001) in BI score, while radiotherapy was associated with a 5-point increase (95%-CI 1.74 to 9.02, <jats:italic>p</jats:italic>≈0.004). However, over time chemotherapy was associated with a score recovery (+ 0.28 points per week, 95%-CI 0.19 to 0.37, <jats:italic>p</jats:italic> &lt; 0.001), whereas for radiotherapy a trend towards BI deterioration was observed (-0.11 points per week, 95%-CI -0.23 to 0.02, <jats:italic>p</jats:italic>≈0.101).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Breast cancer surgery negatively affects BI. BCS and MIBR presumably harm BI less than M in the early postoperative period. Our data suggests BI to be deteriorating in the long term after MIBR while improving after BCS or M. Radiotherapy seems to have an additional negative long-term impact on BI. These findings should be confirmed in further studies to enable evidence-based patient information as part of preoperative shared decision-making and postoperative patient care.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang